The effectiveness of gabapentin in patients with chronic radiculopathy

Yıldırım, Kadir; Sisecioglu, Meltem; Karatay, Saliha; Erdal, Akın; Akın, Levent; Uğur, Mahir; Şenel, Kazım

doi:10.1163/156856903767650718

Cited by 69 publications

(48 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6,57,80,143,156,162,173,176,[214][215][216][217][218][219][220][221][222][223][224][225][226][227][228][229][230] (Two studies were reported in a single publication; 223 studies 696 and 99999.) Seven studies included more than two arms.…”

Section: Description Of Non-opioids Studiesmentioning

confidence: 99%

“…The overall findings from five studies 219,223,224,227,228 showed non-opioids to be significantly better than inactive control for reducing pain. Four studies included patients with acute sciatica, and one poorly reported and poorly conducted RCT 219 included patients with chronic sciatica (evaluating the use of oral gabapentin).…”

mentioning

confidence: 98%

“…Non-opioids were compared with inactive control, opioids, epidural, alternative therapy and biological agents. Five studies 216,223,224,227,228 included only patients with acute sciatica, three 175,215,219 included only patients with chronic sciatica, one 156 did not report the duration of symptoms and the remaining studies included patients with acute or chronic sciatica. The duration of follow-up ranged from 8 hours 227 to 36 days.…”

mentioning

confidence: 99%

“…Four studies included patients with acute sciatica, and one poorly reported and poorly conducted RCT 219 included patients with chronic sciatica (evaluating the use of oral gabapentin). As with the global effect, excluding the study with chronic sciatica improved homogeneity (I 2 = 0%), giving a pooled WMD for four studies of -6.45 (95% CI -10.60 to -2.30).…”

mentioning

confidence: 99%

See 3 more Smart Citations

The clinical effectiveness and cost-effectiveness of management strategies for sciatica: systematic review and economic model

Lewis

Williams²,

Matar³

et al. 2011

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTAThe clinical effectiveness and costeffectiveness of management strategies for sciatica: systematic review and economic model NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA pro...

show abstract

Section: Description Of Non-opioids Studiesmentioning

confidence: 99%

mentioning

confidence: 98%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

The clinical effectiveness and cost-effectiveness of management strategies for sciatica: systematic review and economic model

Lewis

Williams²,

Matar³

et al. 2011

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…2) Gabapentin is efficacious against various pain syndromes such as neuropathic pain, chronic pain, and postoperative pain. 4,[6][7][8][9]12,13) Gabapentin monotherapy is recommended to provide pain relief and to increase the overall quality of life in patients with chronic radicular pain, 14) but the evidence for efficacy against acute pain is limited. 1,2,12) This prospective study analyzed the effects of gabapentin on reduction of the severity of radicular pain, and improvement of the quality of life in patients with LDH and/or LSS over a relatively short period.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Gabapentin for Radiculopathy Caused by Lumbar Spinal Stenosis and Lumbar Disk Hernia

Kasımcan

Kaptan

2010

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

The efficacy of gabapentin monotherapy was investigated against both acute or chronic radicular pain caused by lumbar disk hernia (LDH) or lumbar spinal stenosis (LSS). Seventy-eight patients with radicular pain, 10 males and 68 females aged 23 to 76 years (mean 49.4 years), caused by LSS in 45 patients or LDH in 33 patients were treated with oral administration of gabapentin and were followed up for 3 months. The evaluation included neurological examination, Odom's criteria, visual analog pain scale (VAS), and walking distance. Gabapentin treatment resulted in decreased VAS scores in both groups. Odom's criteria scores had improved to excellent or good in 36 patients with LSS and 28 patients with LDH. Furthermore, walking distance was significantly longer at the 3rd month of the treatment protocol. Eight patients discontinued gabapentin therapy because of the side effects. Gabapentin could be an option in the conservative management of acute or chronic radicular pain.

show abstract

A Clinical Overview of Off-label Use of Gabapentinoid Drugs

2019

View full text Add to dashboard Cite

BACKGROUNDThe gabapentinoid drugs gabapentin and pregabalin were originally developed as antiseizure drugs but now are prescribed mainly for treatment of pain. For gabapentin, the only pain-related indication approved by the US Food and Drug Administration (FDA) is postherpetic neuralgia. For pregabalin, FDA-approved indications related to pain are limited to postherpetic neuralgia, neuropathic pain associated with diabetic neuropathy or spinal cord injury, and fibromyalgia. Despite these limited indications, gabapentin and pregabalin are widely prescribed off-label for various other pain syndromes. Such use is growing, possibly because clinicians are searching increasingly for alternatives to opioids.OBSERVATIONS This report summarizes the limited published evidence to support off-label gabapentinoid uses, describes clinical cases in which off-label use is problematic, and notes how review articles and guidelines tend to overstate gabapentinoid effectiveness.CONCLUSIONS Clinicians who prescribe gabapentinoids off-label for pain should be aware of the limited evidence and should acknowledge to patients that potential benefits are uncertain for most off-label uses.

show abstract

The effectiveness of gabapentin in patients with chronic radiculopathy

Cited by 69 publications

References 17 publications

The clinical effectiveness and cost-effectiveness of management strategies for sciatica: systematic review and economic model

The clinical effectiveness and cost-effectiveness of management strategies for sciatica: systematic review and economic model

Efficacy of Gabapentin for Radiculopathy Caused by Lumbar Spinal Stenosis and Lumbar Disk Hernia

A Clinical Overview of Off-label Use of Gabapentinoid Drugs

Contact Info

Product

Resources

About